Trodelvy: Side Effects & Dosing

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Sacituzumab govitecan

Indications/Uses

Adult patients w/ unresectable locally advanced or metastatic triple -ve breast cancer who have received ≥2 prior systemic therapies, at least 1 of them for metastatic disease; unresectable locally advanced or metastatic hormone receptor +ve, human epidermal growth factor receptor 2 -ve (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy & at least 2 additional systemic therapies in the metastatic setting.

Dosage/Direction for Use

IV 10 mg/kg once wkly on days 1 & 8 of 21-day treatment cycle. Continue treatment until disease progression or unacceptable toxicity. Max dose: 10 mg/kg. Initial infusion should be administered over 3 hr. If prior infusion was tolerated, subsequent infusions should be administered over 1-2 hr.

Contraindications

Severe hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01FX17 - sacituzumab govitecan ; Belongs to the class of other monoclonal antibodies and antibody drug conjugates. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Trodelvy powd for soln for infusion 180 mg

Packing/Price

1's

Trodelvy

sacituzumab govitecan

Manufacturer:

BSP Pharmaceuticals